You are here

  • Home
  • Archive
  • Volume 100, Issue 10
  • Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration

Article info

Article menu
Download PDFPDF
Clinical science
Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration

Authors

  • Katja Hatz Vista Klinik, Binningen, Switzerland Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland University of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Christian Prünte Vista Klinik, Binningen, Switzerland Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland University of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Christian Prünte, Vista Klinik, Hauptstasse 55, Binningen CH-4102, Switzerland; christian{at}pruente.ch
View Full Text

Citation

Hatz K, Prünte C
Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration
British Journal of Ophthalmology 2016;100:1341-1345.

Publication history

  • Received June 10, 2015
  • Revised November 17, 2015
  • Accepted December 16, 2015
  • First published January 11, 2016.
Online issue publication 
October 28, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/